Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HROW NASDAQ:XERS NASDAQ:XFOR NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$36.39-2.9%$39.25$28.54▼$54.85$1.36B0.26746,251 shs110,420 shsXERSXeris Biopharma$8.15-0.8%$7.34$4.87▼$10.08$1.41B0.621.88 million shs173,170 shsXFORX4 Pharmaceuticals$3.84-2.6%$4.00$1.35▼$4.83$360.77M0.35540,820 shs46,869 shsXNCRXencor$19.28-2.9%$14.13$6.92▼$21.26$1.43B0.86827,910 shs118,969 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow-2.57%-15.73%-10.96%-7.46%+3.51%XERSXeris Biopharma-1.32%-4.53%+6.76%+34.81%+63.55%XFORX4 Pharmaceuticals+2.34%+7.07%-1.99%-4.37%+116.48%XNCRXencor+2.16%+5.58%+31.96%+63.46%+114.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$36.39-2.9%$39.25$28.54▼$54.85$1.36B0.26746,251 shs110,420 shsXERSXeris Biopharma$8.15-0.8%$7.34$4.87▼$10.08$1.41B0.621.88 million shs173,170 shsXFORX4 Pharmaceuticals$3.84-2.6%$4.00$1.35▼$4.83$360.77M0.35540,820 shs46,869 shsXNCRXencor$19.28-2.9%$14.13$6.92▼$21.26$1.43B0.86827,910 shs118,969 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow-2.57%-15.73%-10.96%-7.46%+3.51%XERSXeris Biopharma-1.32%-4.53%+6.76%+34.81%+63.55%XFORX4 Pharmaceuticals+2.34%+7.07%-1.99%-4.37%+116.48%XNCRXencor+2.16%+5.58%+31.96%+63.46%+114.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHROWHarrow 2.64Moderate Buy$69.4390.82% UpsideXERSXeris Biopharma 2.57Moderate Buy$10.8032.55% UpsideXFORX4 Pharmaceuticals 2.57Moderate Buy$9.70152.67% UpsideXNCRXencor 2.50Moderate Buy$24.2525.80% UpsideCurrent Analyst Ratings BreakdownLatest XFOR, XNCR, XERS, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)7/21/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.007/20/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/10/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/10/2026XFORX4 Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.007/10/2026XFORX4 Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.007/7/2026XNCRXencor Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$29.00 ➝ $27.007/6/2026XNCRXencor Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/24/2026XNCRXencor Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/4/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHROWHarrow$268.68M5.05$0.82 per share44.49$1.41 per share25.80XERSXeris Biopharma$314.85M4.47$0.10 per share83.06$0.08 per share101.85XFORX4 Pharmaceuticals$35.11M10.31N/AN/A$2.13 per share1.80XNCRXencor$125.58M11.38N/AN/A$8.90 per share2.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHROWHarrow-$5.14M-$0.41N/A16.17N/A-5.57%19.59%2.26%8/10/2026 (Estimated)XERSXeris Biopharma$550K$0.06135.8824.69N/A3.81%735.00%3.24%8/6/2026 (Estimated)XFORX4 Pharmaceuticals-$79.20M-$4.54N/AN/AN/A-1,106.30%-94.90%-48.09%8/6/2026 (Estimated)XNCRXencor-$91.92M-$2.29N/AN/AN/A-177.10%-28.77%-20.52%8/5/2026 (Estimated)Latest XFOR, XNCR, XERS, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026HROWHarrow-$0.23N/AN/AN/A$70.35 millionN/A8/6/2026Q2 2026XERSXeris Biopharma$0.02N/AN/AN/A$90.13 millionN/A8/6/2026Q2 2026XFORX4 Pharmaceuticals-$0.19N/AN/AN/A$2.42 millionN/A8/5/2026Q2 2026XNCRXencor-$0.84N/AN/AN/A$18.89 millionN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 million5/6/2026Q1 2026XFORX4 Pharmaceuticals-$0.20-$0.16+$0.04-$0.16$3.20 million$2.71 million5/6/2026Q1 2026XNCRXencor-$0.7468-$1.71-$0.9632-$1.71$27.86 million$4.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHROWHarrowN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHROWHarrow10.302.482.30XERSXeris Biopharma17.002.121.50XFORX4 Pharmaceuticals0.4510.189.98XNCRXencorN/A6.576.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHROWHarrow72.76%XERSXeris Biopharma42.75%XFORX4 Pharmaceuticals72.03%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipHROWHarrow12.80%XERSXeris Biopharma4.35%XFORX4 Pharmaceuticals1.13%XNCRXencor5.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHROWHarrow18037.28 million32.50 millionOptionableXERSXeris Biopharma290172.64 million165.13 millionOptionableXFORX4 Pharmaceuticals8094.32 million93.25 millionNo DataXNCRXencor28074.14 million70.38 millionOptionableXFOR, XNCR, XERS, and HROW HeadlinesRecent News About These CompaniesEcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCRJuly 28 at 4:01 AM | marketbeat.comXencor (NASDAQ:XNCR) Stock Price Down 6.7% - Should You Sell?July 22, 2026 | marketbeat.comXencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?July 21, 2026 | marketbeat.comXencor (NASDAQ:XNCR) Sees Unusually-High Trading Volume - Here's WhyJuly 20, 2026 | marketbeat.comXencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?July 20, 2026 | zacks.comXencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim DataJuly 19, 2026 | seekingalpha.comXencor Inc.July 17, 2026 | marketwatch.comXencor advances 17% after revealing ESMO 2026 oral presentation slotJuly 17, 2026 | seekingalpha.comXencor (NASDAQ:XNCR) Stock Price Up 7.9% - What's Next?July 17, 2026 | marketbeat.comXencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaJuly 17, 2026 | businesswire.comXencor: Bullish On Their Increasingly In-House PipelineJuly 14, 2026 | seekingalpha.comXencor (NASDAQ:XNCR) Shares Down 6.6% - Should You Sell?July 13, 2026 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 13, 2026 | marketbeat.comXencor Updates Outlook Amid Ultomiris Royalty DisputeJune 19, 2026 | theglobeandmail.comXencor Shareholders Approve Directors, Incentive Plan AmendmentsJune 18, 2026 | tipranks.comXencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets CautionJune 15, 2026 | uk.finance.yahoo.comIncyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trialMay 30, 2026 | seekingalpha.comXencor IncMay 18, 2026 | money.usnews.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comXencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 20263 Overlooked Stocks Positioned for the Next Market RotationBy Bridget Bennett | July 13, 2026XFOR, XNCR, XERS, and HROW Company DescriptionsHarrow NASDAQ:HROW$36.41 -1.05 (-2.81%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Xeris Biopharma NASDAQ:XERS$8.14 -0.07 (-0.79%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.X4 Pharmaceuticals NASDAQ:XFOR$3.84 -0.11 (-2.66%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.Xencor NASDAQ:XNCR$19.24 -0.63 (-3.15%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest? Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
